BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. Other research analysts also ...

The table below from the 10-Q (p. 20) shows the indication for which each of BioMarin's products is approved: BioMarin's latest 10-K (pps. 11-12 ) (the "10-K") includes the following explanatory ...

State of Alaska Department of Revenue cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 25.6% during the 4th quarter, according to the company in its most ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

BioMarin's has signed the first contract with ... 92% of patients still had no need to take prophylactic Factor VIII replacement products at that timepoint, reinforcing the durability of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its portfolio through the development of new therapies and the exploration of novel indications for existing products. The company recently ...

BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Studies have ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock has reached a 52-week low, dipping to $60.77, representing a significant drop from its 52-week high of $94.85. According to InvestingPro data, the ...